latest news releases from the newsroom
Grenville Gold Corp.
Spartan Securities Applies for Listing for Grenville Gold On U.S. Pink Sheets Over the Counter Market
VANCOUVER, British Columbia, June 3, 2008 (PRIME NEWSWIRE) -- Grenville Gold Corporation ("Grenville" or "the Company") (TSX-V:GVG) (Other OTC:GVLGF) (Frankfurt:F9I) (WKN:A0KELU) announces that the Financial Industry Regulatory Authority (FINRA) has accepted the application of Spartan Securities of St. Petersburg, Florida for a quotation on the Pink Sheets for Grenville Gold Stock. For more information on Spartan Securities, please visit their website at www.spartansecurities.com.
U.S. Micro Corp. Announces Acquisition of Computer Equipment Leasing Business
ATLANTA, June 3, 2008 (PRIME NEWSWIRE) -- U.S. Micro Corporation, one of the nation's leading corporate IT asset disposition companies, announced today that it has acquired the computer equipment leasing business of ICON Funding ULC, a subsidiary of New York-based ICON Capital Corp., one of the largest independent, privately held equipment leasing and specialty finance companies in the United States.
Eurand to Be Issued U.S. Patent for Amrix(r)
DAYTON, Ohio, June 3, 2008 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, announced today that the United States Patent and Trademark Office (USPTO) has provided notice that it will award the Company U.S. patent No. 7,387,793 on June 17, 2008, entitled "Modified Release Dosage Forms of Skeletal Muscle Relaxants." The Company will also be awarded a Patent Term Adjustment of an additional 470 days, providing Eurand with coverage on Amrix(r) until at least February 26, 2025.
Lantis Laser Secures Exclusive Worldwide Rights to AXSUN's Advanced Tunable Laser Engine for its OCT Dental Imaging System
DENVILLE, N.J., June 3, 2008 (PRIME NEWSWIRE) -- Lantis Laser Inc. (Pink Sheets:LLSR) (http://www.lantislaser.com) announced today it has signed a Strategic Agreement with AXSUN Technologies, of Billerica, MA, whereby AXSUN will manufacture and supply the Integrated Optical Coherence Tomography (OCT) Engine for Lantis' OCT Dental Imaging System(tm), to be introduced to dentistry in the first quarter of 2009. The OCT Engine is at the core of Lantis' next generation, light based and non-radiation, diagnostic imaging system and enables the forming of an image from captured reflected light of the subject tissue.
Mobile Entertainment Forum
MEF Americas Elects New Board to Accelerate Industry Growth
LOS ANGELES, June 3, 2008 (PRIME NEWSWIRE) -- The Mobile Entertainment Forum (MEF) today announced results of its highly competitive MEF Americas board election, which took place last week to kick off MEFCON 2008, the inaugural event of MEF Americas. The newly elected chair is Jim Beddows, head of content and application partnerships for MSN Mobile at Microsoft. John Orlando, vice president of marketing for LiveWire Mobile, was elected vice chair.
Aztec Oil & Gas, Inc.
Aztec Oil & Gas Announces Drilling of Two New Wells
HOUSTON, June 3, 2008 (PRIME NEWSWIRE) -- Aztec Oil & Gas, Inc. (OTCBB:AZGS) announced that the Company has recently completed the drilling of two new wells for its Aztec 2007A Limited Partnership. The wells, Williams #1 and #2, were drilled in the Tyler County area of West Virginia to a depth of approximately 5,000 feet each. Logs on both wells indicate substantial reserves and look very positive; therefore, fracing and completion of the wells will take place within the next ten days, weather and equipment permitting. It is anticipated that production into pipeline from both wells will begin sometime this month, June 2008.
Nabi Biopharmaceuticals Announces Receipt of $2.5 Million Milestone Payment
ROCKVILLE, Md., June 3, 2008 (PRIME NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) has received a $2.5 million payment from Fresenius USA Manufacturing, Inc. (Fresenius) for the successful completion of another milestone under the agreement governing the Company's 2006 sale of PhosLo(r) (calcium acetate) and the product's related assets to Fresenius for a total consideration of up to $150 million. This milestone payment was contingent on publication of information related to the CARE-2 (Calcium Acetate Renagel Evaluation-2) Study. The twelve month study, published in the June 2008 edition of the American Journal of Kidney Diseases, demonstrated that when lipid levels are kept constant in both treatment groups, there is no difference in cardiovascular calcification between patients treated with PhosLo and those treated with Renagel (sevelamer hydrochloride).